Eli Lilly and Company (NYSE:LLY) Stock Price Up 0.7% - What's Next?

Eli Lilly and Company (NYSE:LLY - Get Free Report)'s stock price rose 0.7% during mid-day trading on Friday . The company traded as high as $872.00 and last traded at $865.49. Approximately 941,755 shares changed hands during trading, a decline of 73% from the average daily volume of 3,426,301 shares. The stock had previously closed at $859.73.

Analysts Set New Price Targets

Several brokerages have recently issued reports on LLY. StockNews.com raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Friday, February 7th. Hsbc Global Res lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday. Leerink Partners set a $950.00 price target on shares of Eli Lilly and Company in a research note on Friday, January 17th. HSBC downgraded Eli Lilly and Company from a "buy" rating to a "reduce" rating and reduced their price objective for the stock from $1,150.00 to $700.00 in a research report on Monday. Finally, Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 target price on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company presently has an average rating of "Moderate Buy" and a consensus target price of $1,000.32.

Eli Lilly and Company Price Performance

The stock has a 50 day moving average of $827.90 and a two-hundred day moving average of $816.88. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The stock has a market cap of $839.64 billion, a PE ratio of 75.62, a PEG ratio of 1.40 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Insider Activity

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. This represents a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.13% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Eli Lilly and Company

Several institutional investors have recently made changes to their positions in LLY. Liberty Square Wealth Partners LLC increased its stake in shares of Eli Lilly and Company by 3.1% during the 1st quarter. Liberty Square Wealth Partners LLC now owns 726 shares of the company's stock worth $600,000 after purchasing an additional 22 shares during the last quarter. Callan Capital LLC raised its holdings in Eli Lilly and Company by 15.7% during the first quarter. Callan Capital LLC now owns 4,745 shares of the company's stock valued at $3,919,000 after buying an additional 645 shares in the last quarter. TD Private Client Wealth LLC lifted its position in shares of Eli Lilly and Company by 3.1% in the first quarter. TD Private Client Wealth LLC now owns 5,607 shares of the company's stock worth $4,631,000 after buying an additional 169 shares during the last quarter. Capital Advisors Inc. OK boosted its stake in shares of Eli Lilly and Company by 16.4% during the 1st quarter. Capital Advisors Inc. OK now owns 6,318 shares of the company's stock worth $5,218,000 after acquiring an additional 892 shares in the last quarter. Finally, Envestnet Asset Management Inc. increased its holdings in shares of Eli Lilly and Company by 17.0% during the 1st quarter. Envestnet Asset Management Inc. now owns 1,112,001 shares of the company's stock valued at $918,413,000 after acquiring an additional 161,665 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.